Tiquizium Bromide

替喹溴胺

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameTiquizium Bromide
Drug Alias Nameチキジウム臭化物ThiatonHSR-902
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMuscarinic acetylcholine receptor M3 antagonists
TargetsMuscarinic acetylcholine receptor M3
Therapy Area/IndicationsGastrospasmUrolithiasisSpasm +[10] 
Global Approved IndicationsGastrospasmUrolithiasisSpasm +[10] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date1984/10/23
Country/TerritoryJapan
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAbbvie IncMylan NvAbbott Laboratories
China Registration ClassN/A

Develop Information

Active CompaniesMylan Epd Lda
Inactive CompaniesN/A
Active IndicationsGastrospasmUrolithiasisSpasm +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeA02B
Related LinksKEGG